$BLUE News
Last published 1y ago
- 1y agoBLUECGbluebird bio Announces Completion of Acquisition by Carlyle and SK CapitalBusiness WireNew management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient
- 1y agoBLUECGCarlyle and SK Capital Partners Announce Expiration of bluebird bio Tender OfferBusiness WireAll conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025 Carlyle (NASDAQ:CG) ("Carlyle"), SK Capital Partners, LP ("SK Capital") and Beacon Parent Holdings,
- 1y agoBLUEbluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK CapitalBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) ("bluebird" or "the Company") today reminds all stockholders to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all outstanding shares of
- 1y agoBLUECGCarlyle, SK Capital Partners and bluebird bio Provide Updated Tender InstructionsBusiness WireStockholders that have previously tendered their shares must re-tender their shares Stockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales
- 1y agoBLUECGCarlyle, SK Capital Partners and bluebird bio Amend Merger AgreementBusiness WireStockholders may elect to receive either $3.00 per share plus CVR of $6.84 per share in cash payable upon achievement of a net sales milestone or $5.00 per share with no CVR bluebird bio, Inc. (NASDAQ:BLUE)
- 1y agoBLUEImportant Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK CapitalBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today reminds all stockholders, including individual stockholders, to promptly tender their shares into the tender offer by Carlyle and SK Capital to purchase all
- 1y agoBLUECGCarlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bioBusiness Wirebluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consideration for their shares and recommends that all stockholders immediately tender their shares
- 1y agoBLUEbluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagementBusiness Wirebluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025 bluebird bio, Inc. (NASDAQ:BLUE)
- 1y agoBLUEbluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today confirmed it has received an unsolicited non-binding written proposal (the "Ayrmid Proposal") from Ayrmid Ltd ("Ayrmid") to acquire bluebird for an upfront cash
- 1y agoBLUEVRTXPFEOnce high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerCNBCBluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
- 1y agoBLUECGbluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalBusiness Wirebluebird stockholders to receive $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, contingent upon offer conditions bluebird's Board of
- 1y agoCVSBLUEVRTXHigh-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsCNBCThe high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.
- 1y agoBLUEbluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness WireStable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring
- 1y agoBLUELong-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb LevelsBusiness WireTreatment effects sustained through long-term follow-up of beyond 10 years in the earliest treated patients (n=2); 81% of participants have >5 years of follow-up bluebird bio, Inc. (NASDAQ:BLUE) today announced
- 1y agoBLUEbluebird bio Announces 1-for-20 Reverse Stock SplitBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock Split") of the Company's common stock following approval by
- 1y agoBLUEbluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access ModelBusiness WireCompany and CMMI agreed to key terms to be offered to State Medicaid Agencies to support access to LYFGENIA™ gene therapy for sickle cell disease States can opt in to an outcomes-based agreement with bluebird
- 1y agoBLUEbluebird bio, Inc. (BLUE) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBLUEbluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceBusiness Wire- 74 patient starts completed or scheduled to date in 2024 across bluebird's commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions;
- 2y agoBLUEbluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results CallBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company
- 2y agoBLUEbluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and
- 2y agoBLUEbluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs). This includes the
- 2y agoPFEVRTXBLUEAGIO+2Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it mattersCNBCPfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.
- 2y agoBLUEbluebird bio Announces Completion of its Q2 2024 Form 10-Q FilingBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that it has completed the filing of its Form 10-Q for the quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q") with the Securities and Exchange Commission ("SEC"). With
- 2y agoBLUEbluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025Business WireActions intended to reduce cash operating expenses by approximately 20% Management team to host conference call today, September 24 at 8:00 am ET Following a comprehensive review of its operations, bluebird bio, Inc.
- 2y agoBLUEbluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-QBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31, 2022, and for each of the first three quarters of 2022 and
- 2y agoBLUEbluebird bio Announces September Investor EventsBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference,
- 2y agoBLUEbluebird bio Announces Receipt of Expected Notices from NasdaqBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that it received notices (the "notices") on August 20, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly
- 2y agoBLUEbluebird bio, Inc. (BLUE) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBLUEbluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceBusiness Wire- 27 patient starts to date in 2024 (19 ZYNTEGLO, 4 LYFGENIA, 4 SKYSONA); anticipate approximately 85 patient starts across the portfolio as LYFGENIA patient starts accelerate in the second half of 2024 - - Second
- 2y agoBLUEbluebird bio Announces Second Quarter 2024 Results Call DateBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET. To participate in the conference call,
- 2y agoBLUEbluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 38,200 shares of common stock to
- 2y agoBLUEbluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)Business Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to
- 2y agoBLUE2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a PartnerPR Newswire2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare...
- 2y agoBLUEbluebird bio Appoints O. James Sterling as Chief Financial OfficerBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of
- 2y agoBLUEInvestors in bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUEPR NewswireThe Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during ...
- 2y agoBLUEbluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights – BLUEGlobeNewswireNEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). Shareholders who purchased shares of BLUE during the class period listed
- 2y agoBLUEbluebird bio, Inc. (BLUE) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoBLUEbluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights – BLUEGlobeNewswireNEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). Shareholders who purchased shares of BLUE during the class period listed
- 2y agoBLUEbluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 GuidanceBusiness Wire- First patient start (cell collection) for LYFGENIA completed – - 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 - - First
- 2y agoBLUEThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio, Inc. Lawsuit - BLUEPR NewswireThe Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during ...
- 2y agoBLUEbluebird bio Announces First Quarter 2024 Results Call Date and Upcoming Investor EventsBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) announced today that it will host a conference call to discuss first quarter 2024 results and business updates on May 9, at 8:00 a.m. ET. To participate in the conference call, please
- 2y agoBLUEbluebird bio Announces Completion of First Cell Collection for LYFGENIA™ Gene TherapyBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) announced today that it has completed the first commercial cell collection for LYFGENIA (lovotibeglogene autotemcel), a one-time gene therapy for the treatment of sickle cell disease in
- 2y agoBLUEShareholders of bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights – BLUEGlobeNewswireNEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). Shareholders who purchased shares of BLUE during the class period listed
- 2y agoBLUESHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BlueGlobeNewswireNEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against bluebird bio, Inc. ("Blue" or the "Company") (NASDAQ:BLUE) and
- 2y agoBLUEbluebird bio Announces Receipt of Expected Notice from NasdaqBusiness Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual
- 2y agoBLUEbluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUEPR NewswireThe Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during ...
- 2y agoBLUEbluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wirebluebird bio, Inc. (NASDAQ:BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of 102,700 restricted stock units ("RSUs") to twelve newly hired employees
- 2y agoBLUEbluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUEPR NewswireThe Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during ...
- 2y agoBLUEbluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – BLUEGlobeNewswireNEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). Shareholders who purchased shares of BLUE during the class period
- 2y agoBLUEbluebird bio, Inc. (BLUE) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts